STAT3 and ovarian carcinoma: It is widely documented that persistently active STAT3 facilitates tumor progression in human PDAC and ovarian cancers in part by inducing anti-apoptosis and pre-metastatic niche formation, thus serving as a potential therapeutic target (38, 41, 42).